- Home
- IMCR vs ICFI Comparison
IMCR vs ICFI Comparison
Compare IMCR & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ICFI
- Stock Information
- Founded
- IMCR 2008
- ICFI 1969
- Country
- IMCR United Kingdom
- ICFI United States
- Employees
- IMCR N/A
- ICFI N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ICFI Professional Services
- Sector
- IMCR Health Care
- ICFI Consumer Discretionary
- Exchange
- IMCR Nasdaq
- ICFI Nasdaq
- Market Cap
- IMCR 1.7B
- ICFI 1.7B
- IPO Year
- IMCR 2021
- ICFI 2006
- Fundamental
- Price
- IMCR $37.97
- ICFI $76.89
- Analyst Decision
- IMCR Buy
- ICFI Buy
- Analyst Count
- IMCR 9
- ICFI 4
- Target Price
- IMCR $67.00
- ICFI $116.75
- AVG Volume (30 Days)
- IMCR 270.5K
- ICFI 212.1K
- Earning Date
- IMCR 11-06-2025
- ICFI 10-30-2025
- Dividend Yield
- IMCR N/A
- ICFI 0.73%
- EPS Growth
- IMCR N/A
- ICFI N/A
- EPS
- IMCR N/A
- ICFI 5.30
- Revenue
- IMCR $379,590,000.00
- ICFI $1,925,502,000.00
- Revenue This Year
- IMCR $30.11
- ICFI N/A
- Revenue Next Year
- IMCR $8.89
- ICFI $2.61
- P/E Ratio
- IMCR N/A
- ICFI $14.48
- Revenue Growth
- IMCR 28.11
- ICFI N/A
- 52 Week Low
- IMCR $23.15
- ICFI $72.03
- 52 Week High
- IMCR $39.33
- ICFI $141.52
- Technical
- Relative Strength Index (RSI)
- IMCR 68.17
- ICFI 31.65
- Support Level
- IMCR $34.30
- ICFI $78.50
- Resistance Level
- IMCR $38.17
- ICFI $84.20
- Average True Range (ATR)
- IMCR 1.54
- ICFI 3.23
- MACD
- IMCR 0.59
- ICFI -0.29
- Stochastic Oscillator
- IMCR 96.54
- ICFI 35.77
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ICFI ICF International Inc.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.